# Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis

> **NCT01535027** · PHASE4 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 125 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** teriparatide
- **DRUG:** teriparatide and raloxifene
- **DRUG:** teriparatide and alendronate

## Key facts

- **NCT ID:** NCT01535027
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01535027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01535027, "Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01535027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*